Surrozen, Inc.: STEMPOINT CAPITAL LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
StemPoint Capital LP amended its Schedule 13G filing on Surrozen, Inc., updating its beneficial ownership stake in the clinical-stage biotechnology company. The amendment was disclosed in an SEC filing under accession number 0001104659-26-127781. Schedule 13G amendments are typically filed when a passive investor's ownership position crosses or adjusts past the 5% threshold, though the filing summary did not specify the exact percentage held. The update signals continued institutional interest in Surrozen, which develops Wnt pathway-targeting antibody therapies. Investors will watch for further 13G/13D activity and any changes in StemPoint's position size in upcoming filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
STEMPOINT CAPITAL LP, Surrozen, Inc.